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Aim: Endothelial dysfunction is considered a premature indication of atherosclerosis and vessel damage and is
present in the postmenopausal period. This study compares the inﬂuence of estrogen, raloxifene and tamoxifen
on factors that affect endothelial function in ovariectomized (OVX) rats.
Main methods: The rats were divided into: SHAM; OVX; OVX + estrogen (0.5 μg/kg/day); OVX + raloxifene
(2mg/kg/day) and OVX+ tamoxifen (1mg/kg/day) groups. The acetylcholine vasorelaxation response was
evaluated in the mesenteric vascular bed. The vascular oxidative stress and serum inﬂammatory cytokine
levels were monitored, and analyses of eNOS and iNOS were performed.
Key ﬁndings: The acetylcholine-induced responses obtained in the OVX were lower than those obtained in
the SHAM, and all treatments restored this response. L-NAME reduced and equalized the acetylcholine-
induced response in all groups. The attenuation of the acetylcholine-induced responses by aminoguanidine
was greater in the OVX. Endothelial dysfunction in OVX was associated with oxidative stress and an in-
crease in iNOS and decrease in eNOS expression. Except for the production of reactive oxidative species
(ROS) in the OVX+ tamoxifen, treatments improved the nitric oxide component of the relaxation response
and normalized both the oxidative stress and the expression of those signaling pathway enzymes. Serum
levels of TNF-α and IL-6 were increased in OVX, and treatments normalized these levels.
Signiﬁcance: Raloxifene and tamoxifen have similar anti-inﬂammatory effects that may be important in im-
proving vascular dysfunction. Tamoxifen did not affect the ROS but improved endothelial dysfunction. The
protective effect on endothelial function by these treatments provides evidence of their potential cardio-
vascular beneﬁts in the postmenopausal period.© 2015 Elsevier Inc. All rights reserved.Introduction
In the postmenopausal period, the decrease in ovarian hormones
can inﬂuence inﬂammation in many tissues, including the vasculature
[3]. The inﬂammatory activation of the endothelium, which plays
a critical role in vascular homeostasis, induces a broad range of
local and systemic responses, including the expression of adhesion
molecules, the production of chemotactic factors (such as cytokines)
and the secretion of chemical mediators (such as free radicals) [12,25].
Evidence demonstrates that after cytokine stimulation, endothelial
cells undergo morphological alterations [2]. An important factor forcal Sciences, Center for Health
chal Campos 1468, 29042-755
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.these endothelial changes is the decreased availability of nitric oxide
(NO). This reduction occurs before the structural manifestation of
vascular disease, such as atherosclerosis, and may thus represent an
independent predictor of potential cardiovascular events [61]. Another
factor that inﬂuences the atherosclerotic process and vessel damage is
an increase in oxidative stress [19,26].
Therapies that involve selective estrogen receptor modulators
(SERMs) have shown protective effects in the treatment of menopausal
symptoms in clinical situations [69,70]. SERMs are a class of synthetic
compounds that act as estrogen receptor antagonists or agonists,
depending on the target tissues [50,58]. Tamoxifen is the most widely
used anti-estrogen for managing breast cancer [23,50]. Raloxifene is
used for the treatment and prevention of post-menopausal osteoporosis
[58]. In addition to these speciﬁc indications, these drugs could be used
to reduce cardiovascular problems that arise in post-menopausal
women. Some clinical and experimental studies have shown that
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function by increasing the synthesis and bioactivity of endothelial fac-
tors [9,16,62], thereby reducing oxidative stress or inﬂammatory
markers [14,17,36,52]. SERMs have acquired a safety proﬁle and have
been shown to exhibit a very low incidence of adverse side effects.
However, along with estrogen therapy, these drugs increase the risk
of venous thromboembolism inpostmenopausalwomen. It is noteworthy
that treatment with estrogen, raloxifene and tamoxifen shifts the
coagulation pattern toward prothrombosis. Patients should therefore be
exhaustively informed about the risks associated with these therapies
[21,22,24,28,40,59,66].
Although long-term in vitro [29] and in vivo [52] studies have
conﬁrmed that SERMs improve cardiovascular dysfunction, several
variables such as gender, endothelial status, vessel type and animal
species appear to affect treatment outcomes. Moreover, the direct
effects of raloxifene and tamoxifen on vascular dysfunction and inﬂam-
matory or oxidative patterns in an estrogen-deﬁcient animal have not
been compared.
Therefore, in this study, we ﬁrst examined whether estrogen,
raloxifene and tamoxifen equally restored the vascular dysfunction
observed in the isolated mesenteric vascular bed from ovariectomized
rats. We then evaluated whether these drugs were able to modify the
participation of endothelial factors in the vascular responses, induce
changes in the oxidative status of the vessel and alter the levels of
inﬂammatory circulating cytokines in an animal model of estrogen
deﬁciency.
Material and methods
Ethical approval
The investigation was conducted in accordance with the biomedical
research guidelines for the care and use of laboratory animals, and the
experimental protocolwas approved by the Ethics Committee inAnimal
Experimentation of the Physiology Sciences Department of the Federal
University of Espirito Santo (no. 012/2008). The experiments were
performed using eight week-old female Wistar rats weighing 180 to
200 g. Throughout the experiment, the animals were housed in groups
in a temperature-controlled room (22 °C) with a 12-h (light)–12-h
(dark) cycle. Standard rat chow and tapwater were available ad libitum.
Animals and treatment
Five groups (n = 06/group) of female rats were studied: SHAM;
ovariectomized (OVX); OVX treated with 17-β-estradiol (EST:
0.5 μg/kg/day; Sigma Chemical Co., St. Louis, MO, USA); OVX treated
with raloxifene (RLX: 2.0 mg/kg/day; Eli Lilly, Indianapolis, IN) and
OVX treated with tamoxifen (TAM; 1.0 mg/kg/day; Sandoz, Cambé,
PR). 17β-Estradiol was dissolved in peanut oil and administered by
subcutaneous injection, and the SERMs were pulverized, dissolved
in water and administered by gavage. These treatments were initiat-
ed 21 days after bilateral ovariectomy and continued for 14 addition-
al days. The effects of ovariectomy and estrogen treatment were
conﬁrmed by measuring the body and uterine weights at the time
of the experiment.
Ovariectomy
Female Wistar rats underwent bilateral ovariectomy after they
were anesthetized with an intraperitoneal injection (i.p.) of keta-
mine (70 mg/kg) and xylazine (10 mg/kg). A bilateral muscle wall
incision wasmade, and both the ovaries and oviductwere exteriorized.
A sterile silk ligaturewas placed around the oviduct and each ovary, and
part of the oviduct was removed with a single cut through the oviduct
near the ovary. The remaining tissue was returned to the peritonealcavity, which was then sutured. The female sham group only
underwent an incision.
Estrous cycle phase determination
Daily vaginal smears were taken from each female sham rat as
previously described [11,18] to conﬁrm that their estrous cycles were
proceeding normally [estrus, metaestrus, diestrus and proestrus]. The
vaginal epithelial cells were examined via a microscope for at least 7
consecutive days before the experiment. The swabs were performed
between 8:00 and 10:00 A.M. tomaintain consistency. The experiments
were performed in the females with normal estrous cycle, during the
proestrus phase.
Vascular reactivity in the mesenteric vascular bed
To test the vascular reactivity responses to acetylcholine (ACh), the
rat mesenteric vascular bed (MVB) was isolated, as described by
Mcgregor [42]. Initially, the superior mesenteric artery, with its
branches, was isolated and perfused with a warmed (37 °C), gassed
(5% CO2 in 95% O2) physiological salt solution with the following
composition: 130 mM NaCl, 4.7 mM KCl, 1.6 mM CaCl2.2H2O, 1.17 mM
MgSO4·6H2O, 14.9 mM NaHCO3, 1.18 mM KH2PO4, 0.026 mM EDTA,
and 11.1 mM glucose, pH 7.4. The MVB was excised from the intestinal
wall and placed in a chamber, and the preparations were allowed to
stabilize for 30 min prior to beginning the experiments. The perfusion
was maintained at a constant rate of 4 ml/min with a roller pump
(Ismatec AS Laboratorium Stechnik, Switzerland). The perfusion pres-
sure was recorded with a pressure transducer (Spectramed P23XL),
and the data were digitized (Acqknowledge for Windows; Biopac
Inc.). The basal perfusion pressure (approximately 40 mm Hg) was
elevated by the addition of norepinephrine (0.1 to 0.3 mM) in the
perfusion ﬂuid to increase the tone by approximately 90–120 mm Hg.
Once a stable tone was established, concentration–response curves to
ACh (1.68 × 10−12 to 1.68 × 10−3 M) were determined in the MVB in
the absence and presence of inhibitors. The ACh doses were adminis-
tered randomly in the MVB. The ACh curves were obtained initially in
each MVB without the presence of inhibitors. To evaluate the effect of
NO availability on vascular reactivity, the preparations were treated
with the nonspeciﬁc NOS inhibitor NG-nitro-L-arginine methyl ester
(L-NAME, 100 mM) and the inducible NO synthase (iNOS) inhibitor
aminoguanidine (AG, 100 mM). The participation of endothelium-
derived hyperpolarizing factor (EDHF) in modulating endothelial func-
tion was assessed by constructing concentration–response curves to
ACh in the presence of L-NAME and the cyclooxygenase (COX) inhibitor
indomethacin (INDO, 2.8 μM), thus excluding the involvement of NO
and prostanoids, respectively. The responses obtained in the presence
of indomethacin and L-NAME represented EDHF-mediated relaxation,
as the remaining relaxation (indomethacin and L-NAME-resistant
relaxation) was completely abolished by 30 mM K+ physiological salt
solution (data not shown). All of these drugs were added to the bath
30 min before obtaining the ACh concentration–response curves.
Western blot analysis
To achieve greater representation of the MVB, mesenteric arter-
ies were carefully dissected to be free of surrounding adipose tissue.
The samples were homogenized and centrifuged at 3000 g for
15 min (4 °C). Protein concentrations were determined using the
method of Lowry [39,53]. The protein lysates [50 μg for eNOS and
iNOS] were separated by 7.5% SDS-PAGE. The proteins were transferred
to polyvinylidene diﬂuoride (PVDF) membranes that were incubated
with mouse monoclonal antibodies for endothelial nitric oxide syn-
thase (eNOS, 1:2500, BD Transduction Laboratories, Lexington, KY,
USA), inducible nitric oxide synthase (iNOS, 1:2000, BD Transduc-
tion Laboratories, Lexington, KY, USA) or β-actin (1:1500, Santa
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membranes were incubated with alkaline phosphatase conjugated
anti-mouse IgG (1:3000, Abcan Inc., MA, USA). The bands were visu-
alized using an NBT/BCIP system (Invitrogen Corporation, CA, USA)
and quantiﬁed using the ImageJ software. The results were calculated
based on the ratio of the density of speciﬁc bands to the corresponding
β-actin.
Determination of vascular ROS formation
The redox-sensitive ﬂuorescent dye dihydroethidine (DHE) was
used to evaluate the in situ formation of reactive oxygen species
(ROS), following a previously describedmethod [30]. Mesenteric arteri-
al rings (3 to 4 mm in length) were embedded in the OCT compound
(Tissue-Tek) and frozen at−80 °C. Transverse sections (8 μm) obtained
using a cryostat were incubated at 37 °C for 30 min with phosphate
buffer. Fresh phosphate buffer containing hydroethidine (2 μM) was
topically applied to each tissue section, and the slices were incubated
in a light-protected humidiﬁed chamber at 37 °C for 30 min to
determine the in situ ROS formation. The negative control sections
received the same volume of phosphate buffer without hydroethidine.
Images were obtained using an optical microscope (DM 2500, Leica
Microsystems, Germany) equipped with a camera using a 40×
objective. The ﬂuorescence intensity in each section was expressed as
the percentage of arbitrary ﬂuorescence units (AFU) in relation to the
SHAM group. Quantiﬁcation of the staining was performed using the
Image ProPlus v.6 software.
Measurement of cytokine levels (TNF-alpha and IL-6)
The animals were decapitated to obtain serum samples after
treatment, and the samples were stored at−80 °C until assayed. IL-6
(catalog KRC0061) and TNF-α (catalog KRC3011) was measured by
ELISA according to manufacturer's speciﬁcations (Biosource Interna-
tional, Camarillo, CA, USA). Each sample (n = 6 per group) was
analyzed in duplicate.
Statistical analysis
The results were presented as means ± standard error of mean
(SEM) for all groups. The Prism 5 software (Graph Pad Software,
San Diego, CA, USA) was used for the statistical analysis. For each
dose–response curve, the maximal response (Emax) and the sensitivity
to ACh were calculated by nonlinear regression analysis as the negative
log of the agonist concentration that produced one-half of the
maximum response (pD2). To compare the effects of some drugs on
the vasodilator responses to ACh, some of the results were expressed
as differences in the area under the concentration–response curves
(dAUC) for the control and experimental groups. These values indicate
whether the magnitude of the effect differed among the groups. For
protein expression, the data were expressed as the ratio between sig-
nals on the blot corresponding to the protein of interest and β-actin.
The differences were analyzed using one or two-way ANOVA followed
by a Tukey test. A difference of P b 0.05was considered to be statistically
signiﬁcant.
Results
The effects of ovariectomy and treatments on body weight
and uterine weight
The corporal weight of the experimental animals was measured
throughout the 35 days of the protocol. No differences existed among
the groups at the beginning of the study. On the last day of treatment,
the OVX group showed a signiﬁcant gain in the corporal weight (CW),
whereas the RLX and EST treatments were able to prevent this gain inthe OVX-treated animals. Conversely, in addition to preventing CW
gain in the ovariectomized animals, the TAM treatment was able to
reduce the ﬁnal CW to values that were lower than those observed for
the SHAM group. As expected, we observed that the ovariectomy signiﬁ-
cantly reduced the uterine weight comparedwith the SHAM group. The
EST treatment restored this reduction, returning the uterine weight to
values comparable to those of the SHAM group. The RLX and TAM
groups had an increase in this parameter compared with the OVX
group, but these treatments did not return the uterine weight to the
normal values compared with the SHAM group. These data are shown
in Table 1.
Effect of raloxifene and tamoxifen treatments on vascular reactivity
The MVB baseline perfusion pressure was not different among the
treatment groups (SHAM: 40.3 ± 1.2; OVX: 41.6 ± 0.9; EST: 40.8 ±
0.8; RLX: 42.4 ± 1.1; TAM: 41.7 ± 1.1 mm Hg), and the perfusion
pressure similarly did not differ after the increase in vascular tone
with norepinephrine (SHAM: 143.9 ± 4.2; OVX: 143.1 ± 5.2; EST:
143.4±4.1; RLX: 140.9±3.5; TAM: 141.1±2.9mmHg). Acetylcholine
induces a concentration-dependent relaxation of the MVB in the rats
(Fig. 1a). The maximum relaxation (Emax) to ACh observed in the OVX
group was reduced compared with that of the SHAM group, while this
decreased response was restored in the MVBs from the EST-, RLX- or
TAM-treated ovariectomized rats (SHAM: 78.6 ± 3; OVX: 59.9 ± 4*;
EST: 80.4 ± 8; RLX: 80.5 ± 4; TAM: 72.3 ± 6 mm Hg; P b 0.01). There
were no changes in the pD2 values among groups for each drug studied
(SHAM: 6.5± 0.2; OVX: 6.7± 0.1; EST: 6.6 ± 0.6; RLX: 6.2± 0.6; TAM:
6.3 ± 0.3).
The nitric oxidemodulation of ACh-induced relaxationwas evaluated
using AG and L-NAME incubation. After incubation with AG, ACh relaxa-
tion (Emax)was signiﬁcantly attenuated in theOVX group, but AGdid not
modify the response inMVBs from the other groups (SHAM: 75.7± 3.2;
OVX: 41.4 ± 4.5**; EST: 78.7 ± 4.4; RLX: 79.8 ± 8.8; TAM: 63.1 ±
3.8 mm Hg; P b 0.01). Treatment with EST, RLX or TAM normalized the
endothelial alterations observed in the OVX group, as shown by the
dAUC values (SHAM: 24.6 ± 8.1; OVX: 53.6 ± 7.2*; EST: 16.2 ± 4.2;
RLX: 11.6 ± 3.2; TAM 8.3 ± 2.2%dAUC; P b 0.01 Fig. 1 b, inset).
L-NAME reduced the vasorelaxation response induced by ACh (Emax)
in all of the groups (Fig. 1c). However, this reduction was higher in the
OVX group than it was in the other groups, as shown by the %dAUC
values (SHAM: 86.5 ± 2.3; OVX: 53.1 ± 5.9*; EST: 76.2 ± 3.1; RLX:
75.6 ± 3.2; TAM 73.2 ± 4.2%dAUC; P b 0.05 Fig. 1 c, inset). These data
suggest a signiﬁcant inﬂuence of NO on the vascular dysfunction
observed in the OVX rats, while the treatments with estrogen, raloxi-
fene and tamoxifen were able to normalize this response. Additionally,
neither L-NAME nor AG altered the pD2 values after ACh-induced
relaxation in the MVBs in any of the groups (L-NAME: SHAM: 6.1 ±
0.3; OVX: 5.9 ± 0.3; EST: 6.6 ± 0.2; RLX: 6.5 ± 0.4; TAM: 6.9 ± 0.8;
AG: SHAM: 6.4 ± 0.2; OVX: 6.3 ± 0.4; EST: 6.4 ± 0.2; RLX: 6.0 ± 0.5;
TAM: 6.9 ± 0.2).
When applied concomitantly, L-NAME and INDO failed to further
alter ACh-induced relaxation and Emax (SHAM: 41.4 ± 6.2; OVX:
36.9 ± 4.5; EST: 39.2 ± 7.8; RLX: 43.7 ± 9.5; TAM: 53.4 ±
7.5mmHg) compared with the response to L-NAME in all of the groups
(Fig. 2). In addition, the AUC values, which showed the magnitude of
EDHF participation in relaxation, were also similar among the groups
(SHAM: 34.1 ± 7.3; OVX: 43.5 ± 6.0; EST: 38.2 ± 9.6; RLX: 34.5 ±
6.2; TAM: 47.1 ± 5.5%AUC, Fig. 2a, inset), indicating that neither
estrogen deﬁciency nor the treatments affected EDHF. The putative
role of prostanoids was assessed using the dAUC (%) values in the pres-
ence of L-NAME and after inhibition with both L-NAME and INDO
(SHAM: 25.1 ± 4.6; OVX: 35.7 ± 6.9; EST: 39.8 ± 7.9; RLX: 44.6 ± 7.1
TAM: 38.4 ± 3.5; %dAUC, Fig. 2b) and showed no differences among
the groups. Additionally, no incremental change in pD2 occurred in
the concentration–response curves in the presence of L-NAME and
Table 1
Effect of ovariectomy and/or treatments on body weight and uterine weight.
SHAM (n = 6) OVX (n = 6) EST (n = 6) RLX (n = 6) TAM (n = 6)
Initial body weight (g) 205 ± 3 202 ± 5 202 ± 4 202 ± 4 198 ± 3
Final body weight (g) 247 ± 1 298 ± 2* 260 ± 4 255 ± 2 213 ± 7†
Uterine weight (g) 0.33 ± 0.03 0.08 ± 0.01* 0.32 ± 0.04 0.24 ± 0.02‡ 0.26 ± 0.01‡
The results are themeans± S.E.M. Parameters measured in the control SHAM, ovariectomized (OVX) and ovariectomized treated with 17β-estradiol (EST), raloxifene (RLX) and tamox-
ifen (TAM) groups. Statistical signiﬁcance is indicated by *P b 0.05 vs. the SHAM group; †P b 0.05 vs. the SHAM, OVX, EST and RLX; ‡P b 0.05 vs. the SHAM, EST group (one-way ANOVA
followed by Tukey's test).
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TAM: 6.1 ± 0.6).Effects of raloxifene and tamoxifen on reactive oxygen species production
To evaluate tissue ROS production, DHE staining was performed in
the mesenteric arteries. At baseline, DHE red ﬂuorescence analysis
revealed an increased production of superoxide anions from themesen-
teric vessels in the OVX rats compared with the SHAM rats. Treatment
with EST or RLX for 14 days corrected the enhanced ROS production in
the mesenteric arteries from OVX rats. However, TAM was not able to
normalize ROS production in the ovariectomized rats (Fig. 3).-10 -8 -6 -4 -2 0 2
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administration of EST, RLX or TAM signiﬁcantly reduced the
values of these cytokines in the ovariectomized-treated rats (EST:
IL-6: 23.9 ± 4.4, TNF-α: 18.9 ± 1.5 pg/ml; RLX IL-6: 16.5 ±
3.7, TNF-α 21.4 ± 1 pg/ml and TAM IL-6: 24.4 ± 1, TNF-α: 20.3 ±
2 pg/ml).
Discussion
The present study demonstrated that chronic treatment with
estrogen, tamoxifen and raloxifene reversed vascular dysfunction in
the MVB to a similar degree in an ovarian hormone-deﬁcient rat
model. Moreover, the present ﬁndings conﬁrm that raloxifene and
tamoxifen have the potential to induce endothelial adaptations similar
to estrogen, primarily those involving NO availability and the produc-
tion of inﬂammatory biomarkers.
Consistent with other in vivo or in vitro studies, this investigation
demonstrates that the loss of estrogen may have profound effects on
the cardiovascular system, resulting in endothelial dysfunction and
other alterations [8,20].
The results of this study suggest that both raloxifene and tamoxifen
have comparable effects to estrogen treatment in restoringNO availabil-
ity in the MVB and, in a similar way, inﬂuence the endothelial dysfunc-
tion observed in estrogen-deﬁciency rats. Our results demonstrated that
the NOS inhibitor L-NAME decreased the ACh relaxing response in all
groups, indicating the importance of NO in the vascular response
in the MVB. In addition, the observation that the magnitude of the
L-NAME (%dAUC) effect was lower in OVX rats suggests that reducedNO bioavailability may be a major determinant of endothelial vascular
alterations in OVX rats. In our study, NO bioavailability in OVX rats
(%dAUC) was higher in the presence of AG, suggesting that the iNOS
isoform could be a major determinant of ACh-induced relaxation in
OVX rats. Endothelial dysfunction, manifested as reduced NO levels, is
one of the most common pathological alterations in cardiovascular
diseases and is characterized by impaired endothelium-dependent
vasodilatation or enhanced vasoconstriction [63]. The clinical impor-
tance of the endothelial NO pathway is well recognized. NO protects
against the development of atherosclerosis in several groups, including
post-menopausal women [6,60,69]. Therefore, the NO pathway is
extremely important in maintaining vascular reactivity, and RLX and
TAM appear to normalize the NO levels.
The results of this study also demonstrated that in the presence of
aminoguanidine (an iNOS inhibitor), the ACh relaxation of OVX rats
was signiﬁcantly attenuated by AG, but AG did not modify the response
in MVBs from the SHAM group. Therefore, iNOS synthase most likely
plays a signiﬁcant role in the production of NO in OVX compared with
other groups. Further, SERM treatment normalized this production.
The functional results observed in the vascular reactivity of these vessels
were conﬁrmed by molecular data. SERM treatment both reduced iNOS
and increased eNOSexpression in themesenteric vessels of OVX, similar
to the estrogen-treated rats. Other studies have observed that treatment
with raloxifene may involve either the stimulation of the eNOS activity
[51] or the greater expression of the eNOS protein [54] in ovariecto-
mized rats.
In healthy vascular tissue, iNOS is usually undetectable [61]. Studies
have shown a relationship between the estrogenic levels and inﬂamma-
tory processes. Nweze et al. [48] demonstrated that in hepatocytes, es-
trogen treatment decreased iNOS mRNA levels and protein expression
in cytokine-stimulated cells. The anti-inﬂammatory action of raloxifene
has been demonstrated in lipopolysaccharide (LPS)-induced murine
macrophage RAW264.7 cells by reduced pro-inﬂammatory genes such
as iNOS [34]. However, evidence has demonstrated that in OVX rats
treatedwith raloxifene, the endothelial immunoreactivity of iNOS levels
in thoracic aortas was signiﬁcantly increased compared with the OVX
group [10]. The differences between our data and these observations
may be explained in part by the type of vessel (thoracic aorta, a
conductance vessel and mesenteric bed, resistance vessels) and the
role of age-related vascular changes (two-month-old female rats were
used in this study, and 12- to 15-month-old female rats were used in
the other study). Previously, we showed that tamoxifen attenuated
the vasoconstriction induced by ACh and increased the adenosine-
induced vasodilator response in the coronary vascular bed, suggesting
that tamoxifen has beneﬁcial effects on vascular reactivity [9]. Addition-
ally, Mark et al. [41] demonstrated that tamoxifen treatment resulted in
a decrease in mean arterial blood pressure and affected vascular
reactivity in the mesenteric vascular bed in ovariectomized rats. More-
over, estrogen deﬁciency might contribute to impaired endothelial
function by reducing EDHF [38,47,57]. In our study, the association
between L-NAME and INDO revealed that EDHF was not altered by
estrogen deﬁciency, estrogen or SERM treatment in the MVBs. The
%AUC values also supported this ﬁnding, which, when taken together,
suggest that NO may be reduced in the OVX rats independent of
EDHF, as reported in other studies [11,13].
The available evidence suggests that SERMs are capable of acting
directly on both endothelial cells and the underlying vascular smooth
muscle cells, resulting in a multitude of favorable modiﬁcations of the
vascular wall that contribute to improved local blood ﬂow [1,37].
However, these therapies should only be used after careful consider-
ation of the risk–beneﬁt ratio in postmenopausalwomenwith a person-
al history of cardiovascular disease [7,15].
Most in vitro studies have demonstrated that ROS reduces the
availability of the eNOS substrate and/or cofactor levels in endothelial
cells [11,20,70]. An increase in superoxide (O2−), an important ROS,
occurs concurrentlywith a decrease in NObioavailability. The superoxide
Fig. 3. Effect of 17β-estradiol (EST), raloxifene (RLX) and tamoxifen (TAM) treatment on oxidative stress in the mesenteric arteries from ovariectomized rats. Representative DHE staining in
mesenteric arteries from the control (SHAM) (a), ovariectomized (OVX) (b) and ovariectomized treated with EST (c), RLX (d), and TAM (e) groups (upper panel). The ﬂuorescent intensity
was quantiﬁed based on the red signal (magniﬁcation 40×).
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bioavailability [56]. With this consideration in mind, we performed the
DHE analysis to evaluate the ROS production. This analysis revealed
that the production of ROS in the OVX rats was dramatically increased
compared with the SHAM values, conﬁrming previous reports [11,44,
49]. The RLX-treated rats, however, showed reduced ROS formation in
the mesenteric arteries, similar to the OVX animals that received
estrogen. In postmenopausal women, raloxifene treatment reduces the
plasmatic oxidative stress indices and the levels of adhesion molecules
[16]. However, there are limited animal studies available that have inves-
tigated the antioxidant properties of raloxifene via chronic treatment in
the vessel. Though a reduction in oxidative stress from vascular cellshas been observed in SHR [67] and ovariectomized rats [4] that received
RLX chronically, these studies did not evaluate vascular reactivity.
The two SERMs used in this study had similar effects on vascular
reactivity and protein expression. However, we observed differences
in the oxidative stress analyses. TAM treatment did not normalize the
increased ROS production observed in the OVX group. Our study is
in agreementwith that of Vitseva et al. [64], who demonstrated a signif-
icant increase in superoxide release with the tamoxifen metabolites in
platelet activity or altered platelet generation. This change normalized
when a superoxide dismutase mimetic was added. Another study
conducted by Lee et al. [35] demonstrated that in patients with breast
cancer, treatment with tamoxifen induced ROS while treatment with
Fig. 4. Effect of 17β-estradiol (EST), raloxifene (RLX) and tamoxifen (TAM) treatment on the expression of signaling pathway proteins. Western blot analysis of eNOS and iNOS in the
mesenteric vascular beds from the control (SHAM), ovariectomized (OVX) and ovariectomized treated with EST, RLX and TAM groups (upper panels, representative blots). The column
graphs refer to the densitometric analysis of the bands normalized to total β-actin expression. Each column represents themean of 6 experiments ± S.E.M. **P b 0.01 and *P b 0.05 vs. the
SHAM group by one-way ANOVA followed by Tukey's test.
107A.Z. Lamas et al. / Life Sciences 124 (2015) 101–109an ROS scavenger abolished ROS generation in those patients. However,
our group demonstrated that the use of tamoxifen in women after
chemotherapy for the treatment of breast cancer signiﬁcantly reduced
the levels of cardiovascular disease risk markers such as C-reactive
protein, apolipoprotein A-1 and apolipoprotein B-100 [55]. Although
unable to normalize the ROS production, TAM normalized the vascular
dysfunction and both the inﬂammatorymarkers and endothelial factors
altered in OVX rats. The role of inﬂammation both in the early stages of
disease and during disease progression is becoming increasingly recog-
nized [61]. TNF-α has been shown to play an important role in driving
the expression of iNOS in inﬂammatory states, suggesting that the
effects of cytokines on vascular cells may also involve increases in ROS
formation and impairment in vascular reactivity [27,31].
Considering the importance of cytokines in the development of
inﬂammatory alterations in the vascular wall [33,45], we evaluated
the plasma concentration of cytokines in our study. Our results demon-
strated an increase in the serum levels of pro-inﬂammatory cytokines
(IL-6 and TNF-α) in OVX animals, whereas treatment with raloxifene
and tamoxifen normalized these altered levels. This result conﬁrms
that estrogen modulates inﬂammation in an estrogen-deﬁcient state.
Kauser et al. [32] demonstrated that 17β-estradiol decreases cytokine-
induced nitrite accumulation and restores depressed contractile reactiv-
ity in endothelium-denuded aortic rings. This effect was mediated by
decreasing IL-1-β and increasing the levels of iNOS mRNA and protein
in this vascular tissue. Our previous study [43] and that of Arenas et al.SHAM OVX EST RLX TAM
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Fig. 5. Effect of 17β-estradiol (EST), raloxifene (RLX) and tamoxifen (TAM) treatment on the e
control (SHAM), ovariectomized (OVX) and ovariectomized treated with EST, RLX and TA
*P b 0.05 vs. the SHAM group by one-way ANOVA followed by Tukey's test.[2] demonstrated that OVX rats had elevated serum levels of TNF-α
and IL-6 and that estrogen treatment was able to reduce these levels.
Similarly, other studies in humans have shown that the removal of
estrogen may increase the release of the pro-inﬂammatory cytokines
IL-1β, IL-6 and TNF-α and that the administration of estradiol may
inhibit the expression and release of these cytokines [5,46,71]. Studies
in postmenopausal women have proposed that raloxifene has anti-
inﬂammatory effects as a result of its inﬂuence on cytokines, such as
IL-6, TNF-α, TGF-β, and other factors, such as growth factors [65,68].
We present evidence supporting the effectiveness of raloxifene
and tamoxifen in modulating inﬂammatory markers in an estrogen-
deﬁcient state. These ﬁndings may have important implications for
the treatment of post-menopausal cardiovascular and immunological
complications.Conclusion
In conclusion, our results indicate that endothelial dysfunction sec-
ondary to estrogen deﬁciency in ovariectomized rats is normalized by
raloxifene and tamoxifen to a similar degree by inhibiting inﬂammatory
mediators in MVB. When raloxifene or tamoxifen is used at an early
stage of estrogen deﬁciency, they have a protective effect on endothelial
function as evidenced by the reduction in the number of risk biomarkers
of major cardiovascular changes that result in a signiﬁcant positiveSHAM OVX EST RLX TAM
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xpression of cytokines. Elisa analysis of IL-6 (a) and TNF-alpha (b) in the serum from the
M groups. Each column represents the mean of 6 experiments ± S.E.M.**P b 0.01 and
108 A.Z. Lamas et al. / Life Sciences 124 (2015) 101–109modulation of endothelial-dependent vasodilatation. However, large
clinical trials are necessary to determine whether these beneﬁcial
effects are maintained over the long term.
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